Durvalumab + Oleclumab
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Ductal Adenocarcinoma
Conditions
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
Trial Timeline
Jan 1, 2021 → Jan 1, 2023
NCT ID
NCT04262388About Durvalumab + Oleclumab
Durvalumab + Oleclumab is a phase 2 stage product being developed by AstraZeneca for Pancreatic Ductal Adenocarcinoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04262388. Target conditions include Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04262375 | Phase 2 | Withdrawn |
| NCT04262388 | Phase 2 | Withdrawn |
| NCT03875573 | Phase 2 | Active |
| NCT03773666 | Phase 1 | Completed |
Competing Products
20 competing products in Pancreatic Ductal Adenocarcinoma